Successful treatment of early secondary myelofibrosis in SLE with IVIG

A. Aharon, Y. Levy, Y. Bar-Dayan, A. Afek, G. Zandman-Goddard, Y. Skurnik, F. Fabrrizzi, Y. Shoenfeld

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


Myelofibrosis has been reported as a rare cause of pancytopenia in patients with autoimmune diseases. We describe a 54 y old female patient who was admitted with severe anemia subsequently found to be due to marrow fibrosis. During the course of her hospitalization, relying both on her clinical symptoms as well as the results of a wide range of laboratory tests and diagnostic procedures, the diagnosis of systemic lupus erythematosus was established. The patient was treated with high dose steroids, but improvement of her clinical symptoms as well as normalization of her peripheral blood count were achieved only after high dose intravenous therapy with gamma globulin (IVIG) was instituted. Along with the improvement in the peripheral blood parameters normalization of the bone marrow architecture was recorded on a repeated bone marrow biopsy. IVIG therapy should be considered in extreme cases of bone marrow suppression in SLE.

Original languageEnglish
Pages (from-to)408-411
Number of pages4
Issue number4
StatePublished - 1 Jan 1997
Externally publishedYes


  • Intravenous immunoglobulin
  • Secondary myelofibrosis
  • Systemic lupus erythematosus

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Successful treatment of early secondary myelofibrosis in SLE with IVIG'. Together they form a unique fingerprint.

Cite this